These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 35378070)
1. Dapagliflozin in young people with type 2 diabetes. Tommerdahl KL; Nelson RG; Bjornstad P Lancet Diabetes Endocrinol; 2022 May; 10(5):303-304. PubMed ID: 35378070 [No Abstract] [Full Text] [Related]
2. Clinical parameters affecting dapagliflozin response in patients with type 2 diabetes. Lee JY; Kim G; Kim SR; Lee YH; Lee BW; Cha BS; Kang ES Diabetes Metab; 2017 Apr; 43(2):191-194. PubMed ID: 28089373 [No Abstract] [Full Text] [Related]
3. Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus. Davis PN; Ndefo UA; Oliver A J Pharm Pract; 2016 Apr; 29(2):165-71. PubMed ID: 25609661 [TBL] [Abstract][Full Text] [Related]
4. Empagliflozin (Jardiance) for Type 2 Diabetes Mellitus. Zimmermann J Am Fam Physician; 2016 Dec; 94(12):1014-1015. PubMed ID: 28075091 [No Abstract] [Full Text] [Related]
5. Dapagliflozin-Associated Diabetic Ketoacidosis. Chakinala RC; Chang AP; Solanki S; Haq KF; Cho R Am J Ther; 2018; 25(6):e765-e766. PubMed ID: 29672334 [No Abstract] [Full Text] [Related]
6. [New drugs in type 2 diabetes mellitus therapy]. Kvapil M Vnitr Lek; 2013 Aug; 59(8):713-8. PubMed ID: 24007229 [TBL] [Abstract][Full Text] [Related]
7. Benefit of Dapagliflozin When Used With Cardiovascular Medications in Patients With Type 2 Diabetes. Slomski A JAMA; 2022 Sep; 328(9):817. PubMed ID: 36066528 [No Abstract] [Full Text] [Related]
8. Antidiabetic Drug Approved to Reduce Risk of Kidney Disease. Aschenbrenner DS Am J Nurs; 2021 Sep; 121(9):25. PubMed ID: 34438427 [TBL] [Abstract][Full Text] [Related]
9. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Rosenstein R; Hough A N Engl J Med; 2016 Mar; 374(11):1093-4. PubMed ID: 26981944 [No Abstract] [Full Text] [Related]
10. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Edwards JL N Engl J Med; 2016 Mar; 374(11):1093. PubMed ID: 26981943 [No Abstract] [Full Text] [Related]
11. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Fischereder M; Schönermarck U N Engl J Med; 2016 Mar; 374(11):1092-3. PubMed ID: 26981942 [No Abstract] [Full Text] [Related]
12. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Sarafidis PA; Tsapas A N Engl J Med; 2016 Mar; 374(11):1092. PubMed ID: 26981941 [No Abstract] [Full Text] [Related]
13. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Zinman B; Lachin JM; Inzucchi SE N Engl J Med; 2016 Mar; 374(11):1094. PubMed ID: 26981940 [No Abstract] [Full Text] [Related]
15. Dapagliflozin, an SGLT2 inhibitor, for diabetes. Hanefeld M; Forst T Lancet; 2010 Jun; 375(9733):2196-8. PubMed ID: 20609956 [No Abstract] [Full Text] [Related]
16. Dapagliflozin: drug profile and its role in individualized treatment. Sposetti G; MacKinnon I; Barengo NC Expert Rev Cardiovasc Ther; 2015 Feb; 13(2):129-39. PubMed ID: 25560982 [TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin approved for type 2 diabetes. Traynor K Am J Health Syst Pharm; 2014 Feb; 71(4):263. PubMed ID: 24481146 [No Abstract] [Full Text] [Related]
18. Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: "and Death Shall Have no Dominion"? Papanas N; Tsioufis C; Maltezos ES Curr Vasc Pharmacol; 2016; 14(4):316-8. PubMed ID: 26924324 [No Abstract] [Full Text] [Related]
19. Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes. Ingelfinger JR; Rosen CJ N Engl J Med; 2015 Nov; 373(22):2178-9. PubMed ID: 26605932 [No Abstract] [Full Text] [Related]